Women s Interagency HIV Study (WIHS) IV, Limited Competition (U01)

The summary for the Women s Interagency HIV Study (WIHS) IV, Limited Competition (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Women s Interagency HIV Study (WIHS) IV, Limited Competition (U01): -This limited competition RFA solicits applications to continue projects currently funded at the seven sites for the Women s Interagency HIV Study (WIHS) for a 5-year period beginning November 1, 2007. The WIHS is a multi-site prospective epidemiology cohort study of women in the United States who are either infected with HIV or at increased risk for such infections. The WIHS cohort was established in 1994 and has participated in follow-up visits at six-month intervals since that time. The study is currently funded by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Child Health and Human Development (NICHD), the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI). Due to the longitudinal data collected and need for continuing follow-up, competition will be restricted to the seven current WIHS institutions. -The specific objective and scope for continuing the WIHS Study is to address research questions on the natural and treated history of HIV infection in a representative cohort of women in the United States as well as emerging questions concerning HIV infection and treatment. The WIHS, by prospectively studying a cohort of predominantly minority women with or at high risk for HIV infection, is providing detailed information relevant to the evolving biological and psychosocial characteristics of the HIV/AIDS epidemic in U.S. women as we move into a second decade of antiretroviral therapy. -This RFA will use the U01 (Cooperative Agreement) mechanism.